Bellicum Pharmaceuticals Stock Total Asset
| BLCMDelisted Stock | USD 0.37 0.05 11.90% |
Bellicum Pharmaceuticals fundamentals help investors to digest information that contributes to Bellicum Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Bellicum Pink Sheet. The fundamental analysis module provides a way to measure Bellicum Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellicum Pharmaceuticals pink sheet.
Bellicum |
Bellicum Pharmaceuticals Company Total Asset Analysis
Bellicum Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Bellicum Pharmaceuticals Total Asset | 23.82 M |
Most of Bellicum Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellicum Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Bellicum Pharmaceuticals has a Total Asset of 23.82 M. This is 99.68% lower than that of the Biotechnology sector and 98.79% lower than that of the Health Care industry. The total asset for all United States stocks is 99.92% higher than that of the company.
Bellicum Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellicum Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellicum Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Bellicum Pharmaceuticals by comparing valuation metrics of similar companies.Bellicum Pharmaceuticals is currently under evaluation in total asset category among its peers.
Bellicum Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (19.69) % | |||
| Current Valuation | (38.62 M) | |||
| Shares Outstanding | 9.5 M | |||
| Shares Owned By Insiders | 4.19 % | |||
| Shares Owned By Institutions | 29.30 % | |||
| Number Of Shares Shorted | 1.44 M | |||
| Price To Earning | 8.50 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5.46 X | |||
| Revenue | 1.5 M | |||
| Gross Profit | (17.38 M) | |||
| EBITDA | (28.93 M) | |||
| Net Income | (24.97 M) | |||
| Cash And Equivalents | 33.17 M | |||
| Cash Per Share | 3.85 X | |||
| Total Debt | 58 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 8.07 X | |||
| Book Value Per Share | (1.11) X | |||
| Cash Flow From Operations | (25.78 M) | |||
| Short Ratio | 0.17 X | |||
| Earnings Per Share | (1.57) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 13 | |||
| Beta | 1.57 | |||
| Market Capitalization | 3.52 M | |||
| Total Asset | 23.82 M | |||
| Retained Earnings | (575.42 M) | |||
| Working Capital | 20.03 M | |||
| Current Asset | 96.89 M | |||
| Current Liabilities | 7.45 M | |||
| Z Score | -0.31 | |||
| Net Asset | 23.82 M |
About Bellicum Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellicum Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellicum Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellicum Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |